3'-Methoxy-3,4',5,7-tetrahydroxyflavone (isorhamnetin) is a plant flavonoid that occurs in fruits and medicinal herbs. Isorhamnetin exerts anticancer effects, but the underlying molecular mechanism of the chemopreventive potential of isorhamnetin remains unknown. Here, we report anti-skin cancer effects of isorhamnetin. Isorhamnetin inhibited epidermal growth factor (EGF)-induced neoplastic cell transformation. It also suppressed anchorage-dependent and -independent growth of A431 human epithelial carcinoma cells.
Introduction
Non-melanoma skin cancer (NMSC) is the most commonly diagnosed cancer in the United States. About 1.3 million individuals suffer from this disease (1) . The most common types of NMSC are basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). BCC and SCC develop from basal cells and keratinocytes, respectively. BCC comprises 75% of all NMSC cases, and SCC makes up 20%. SCC, but not BCC, can metastasize to other areas of the body (2) . Because NMSC is readily detectable and has limited malignancy, the mortality of NMSC is low, compared with other cancers (3) . However, because of its high incidence, NMSC is the fifth most costly cancer in the United States. Medicare spends $13 billion each year on skin cancer treatment (4) . Changing environmental conditions, such as the destruction of the ozone layer and environmental pollution, and alterations in eating habits and increased longevity enhance the incidence of NMSC (5) . A suitable chemopreventive agent could prevent and cure NMSC, which would help people avoid the pain of skin cancer and reduce Medicare costs (6) .
Ultraviolet (UV) radiation is the most important cause of skin cancer and chronic illnesses and carcinogenic chemical exposures are also major factors (1) . These causes of skin cancer activate multiple cellular signaling pathways and convert normal cells to cancerous cells. An important mediator of these signaling pathways is the epidermal growth factor receptor (EGFR). The EGFR belongs to the ErbB family of receptor tyrosine kinases (RTKs). This receptor is dimerized by binding a ligand, such as EGF (7), which activates the intercellular tyrosine kinase domain. The activated EGFR tyrosine kinase domain activates the mitogen-activated protein (MAP) kinases and phosphoinositide 3-kinase (PI3-K) (8) .
Previous studies have shown that the EGFR is required for UV-induced NMSC development (9) . Chemical carcinogens, such as arsenite, also activate EGFR signal transduction. Both CAN-10-2783 R1 5 SCC and BCC highly overexpress the EGFR (10) . Thus, a compound that targets the EGFR signaling pathway might be useful in NMCS prevention and treatment.
COX-2 plays a crucial role in inflammation, tumorigenesis, and angiogenesis. It is overexpressed in many types of cancer. The development of intestinal tumors and skin papillomas were reportedly reduced in a COX-2 knockout mouse model (11) . The pharmacological inhibition of COX-2 also impaired tumor formation in many animal models (12) and COX-2 is apparently required for neoplastic transformation (13) . Thus, the inhibition of COX-2 expression might also be a promising target for preventing carcinogenesis.
3'-Methoxy-3,4',5,7-tetrahydroxyflavone (i.e., isorhamnetin) is an active compound in herbal medicines, such as Persicaria thunbergii H. and gross Hippophae rhamnoides L., and it has been used to treat cardiovascular disease, rheumatism, and hemorrhage (14) (15) (16) . Recent studies demonstrated that isorhamnetin exerts anticancer effects. Isorhamnetin inhibits the proliferation of several cancer cell lines and suppresses the weight and size of tumors of Lewis lung carcinoma cell allografts in mice (15, 17, 18) . However, the inhibitory effect of isorhamnetin on skin cancer and the underlying molecular mechanisms are not fully understood. In the current study, we examined the inhibitory effects of isorhamnetin against skin cancer and we suggest MEK1 and PI3-K as novel targets of isorhamnetin.
Materials and Methods
Chemicals and reagents. Isorhamnetin was purchased from Sigma Aldrich (St. Louis, MO) and its purity is over 95%. EGF was purchased from R&D Systems (Minneapolis, MN).
Antibodies were from Cell Signal Biotechnology (Beverly, MA) and Santa Cruz Biotechnology (Santa Cruz, CA). The MEK1 and PI3-K assay kits were obtained from Western blot analysis. Western blot analyses were performed as described in our previous studies (19) .
Anchorage-independent cell transformation assay. This assay was performed as reported in our previous studies (19) .
Cell Viability. Cell viability was assessed as explained in our previous studies (19 Luciferase assays for COX-2 promoter activity and AP-1 transcription activity. The luciferase activity was determined as previously reported (19) .
Kinase assays. Kinase assays were conducted as reported in our previous studies (19, 20) .
Direct and cell-based pulldown assays. Active MEK1 protein, PI3-K (200 ng), or a JB6 cellular supernatant fraction (500 μg) was incubated with isorhamnetin-Sepharose 4B or Sepharose 4B beads alone as a control (100 μL, 50% slurry) in reaction buffer (50 mM Tris, pH 7.5, 5 mM EDTA, 150 mM NaCl, 1 mM DTT, 0.01% Nonidet P-40, 2 μg/mL BSA, 0.02 mM PMSF, and 1× protease inhibitor mixture). After incubation with gentle rocking overnight at 4°C, the beads were washed 5x with reaction buffer (50 mM Tris, pH 7.5, 5 mM EDTA, 150 mM NaCl, 1 mM DTT, 0.01% Nonidet P-40, and 0.02 mM PMSF), and proteins bound to the beads were analyzed by Western blotting.
ATP and isorhamnetin competition assay. Recombinant MEK1 or PI3-K (0.2 µg) was incubated with 100 µL of isorhamnetin-Sepharose 4B or 100 µL of Sepharose 4B beads in reaction buffer (see above) for 12 h at 4°C, and ATP was added at either 10 or 100 µM to a final volume of 500 µL, followed by incubation for 30 min. The samples were washed and proteins were detected by Western blotting. Statistical analysis. When necessary, data are expressed as means ± S.D. and a one-way ANOVA was used for single statistical comparisons. A probability value of p < 0.05 was used as the criterion for significance.
Results

Isorhamnetin strongly inhibits EGF-induced neoplastic transformation of JB6 cells
and anchorage-dependent and -independent cell growth of A431 cells. We first examined the effects of isorhamnetin on EGF-induced neoplastic transformation in JB6 cells. Based on the numbers of cell colonies, EGF-promoted neoplastic transformation was markedly inhibited in JB6 cells treated with 10 µM isorhamnetin (Fig. 1A, B) . Isorhamnetin between 10 and 40 µM had no effect on cell viability after 3 days (Supplemental Fig. 1 ), suggesting that isorhamnetin inhibits EGF-induced neoplastic transformation without affecting viability of JB6 cells. Because A431 cells overexpress EGFR and are able to grow in athymic nude mice, this is an excellent model for studying EGF-mediated skin cancer (21) . We measured anchorage-dependent and -independent cell growth of A431 cells by MTS assay and a soft agar assay, respectively. Isorhamnetin suppressed both anchorage-dependent and -independent growth of A431 cells (Fig. 1C, 1D ).
Isorhamnetin suppresses COX-2 protein expression in JB6 and A431 cells. Because
COX-2 is one of the most important inflammatory mediators of skin cancer (22), we examined the effects of isorhamnetin on EGF-induced COX-2 expression in JB6 cells. COX-2 expression was inhibited dose-dependently by isorhamnetin treatment ( determine whether the inhibitory effects of isorhamnetin on COX-2 expression are mediated by transcriptional regulation, we investigated the effects of isorhamnetin on EGF-induced cox-2 promoter activity. The luciferase assay revealed that exposure to EGF (10 ng/mL) significantly induced cox-2 promoter activity, and it was suppressed by isorhamnetin treatment in a dose-dependent manner (Fig. 2B) . JB6 P cells stably transfected with an AP-1 luciferase reporter plasmid were used to measure AP-1 transactivation, which is a wellknown transcription factor regulating COX-2 expression. Isorhamnetin inhibited EGFinduced AP-1 transactivation (Supplemental Fig. 2 ) in a dose-dependent manner. Next, we examined the effect of isorhamnetin on COX-2 protein expression in A431 cells and found that after 12 h of treatment with 40 μM isorhamnetin, COX-2 expression had completely disappeared (Fig. 2C) . Isorhamnetin from 10 μM also suppressed COX-2 expression completely in A431 cells (Fig. 2D) .
Isorhamnetin suppresses growth and COX-2 expression in A431 xenograft tumors in
nude mice. Because isorhamnetin was observed to be effective in suppressing the proliferation of A431 cells, we studied the effects of isorhamnetin in an in vivo xenograft model to further confirm the anti-tumorigenic activity of isorhamnetin. No significant body weight loss or appearance change was observed in mice treated with isorhamnetin, compared with controls, indicating that the doses used were not toxic to the animals (Supplemental Fig.3 ). Photographic data demonstrated that isorhamnetin treatment suppressed tumor development in mice (Fig. 3A) . (Fig. 3C) . Collectively, these results suggest that isorhamnetin might serve as an effective anticancer treatment with the potential to suppress or delay the tumorigenicity of A431 cells in an in vivo system. To further confirm the inhibitory effect of isorhamnetin on COX-2 protein expression in an in vivo model, we examined the level of COX-2 expression in xenograft tumors of athymic nude mice by immunohistochemical analysis. Consistent with the results using A431 cells, the levels of COX-2 expression in the isorhamnetin-treated groups were lower than in the control group (Fig. 3D) . 
Isorhamnetin inhibits the phosphorylation of ERKs and
indicated that isorhamnetin strongly inhibited MEK1 kinase activity (Fig. 5A-a) and also suppressed EGF-induced MEK1 activity (Fig. 5A-b) . Because isorhamnetin attenuated the EGF-induced Akt/p70S6K pathway, and PI3-K is an upstream kinase of Akt, we investigated whether PI3-K was another molecular target of isorhamnetin. We found that isorhamnetin inhibited PI3-K in vitro (Fig. 5B-a) and ex vivo (Fig. 5B-b) .
Next, we investigated whether isorhamnetin interacted directly with MEK1 or PI3-K.
The direct binding of isorhamnetin to MEK1 or PI3-K was demonstrated by an in vitro pulldown assay (Fig. 5C-a, 5D-a) . Additionally, we observed ex vivo binding between isorhamnetin and MEK1 or PI3-K in JB6 cell lysates (Fig. 5C-b and 5D-b) .
Isorhamnetin binds to MEK1 in an ATP-noncompetitive manner and to PI3-K in an
ATP-competitive manner. We determined whether the direct binding between isorhamnetin and MEK1 or PI3-K occurred in an ATP-competitive manner. Results indicated that with increasing concentrations of ATP, the amount of MEK1 bound to isorhamnetin-Sepharose beads remained constant (Fig. 6A) , whereas the amount of PI3-K bound to isorhamnetinSepharose beads decreased with increasing concentrations of ATP (Fig. 6B) . Thus, isorhamnetin bound to MEK1 in an ATP-noncompetitive manner and to PI3-K in an ATPcompetitive manner. Thus, to predict the binding mode between isorhamnetin and MEK1 or PI3-K, we conducted a molecular modeling study. Considering the experimental observation that isorhamnetin binds to MEK1 noncompetitively with ATP, we docked this compound into the pocket separate from but adjacent to the ATP binding site, similar to PD318088 in the crystal structure of the MEK1-PD318088 complex (Fig. 6C) (24) . The putative binding mode To further investigate the binding mode of isorhamnetin to PI3-K, we also conducted a modeling study using the crystal structure of PI3-K in complex with ATP or quercetin (25, 
Discussion
EGFR is a receptor tyrosine kinase that mediates multiple signaling pathways, including the MEK/ERKs and PI3-K pathways that regulate cell proliferation (27) . The EGFR is an important drug target in cancer and it acts as a strong prognostic factor (8) . This receptor is expressed abundantly in the basal layer of the epidermis and in the outer sheath of hair follicles, and is highly overexpressed in NMSC (28) . EGFR mediates the signaling pathway induced by major etiologic factors of skin cancer including UV light and heavy metal exposure. Activated EGFR promotes AP-1 transactivation by mediating signaling pathways such as PI3-K and MEK/ERKs (7). These pathways induce many inflammatory genes, such as cox-2, which play pivotal roles in skin carcinogenesis (29) . Here, we studied the inhibitory effects of a natural compound, isorhamnetin, on EGFR-mediated skin cancer.
To verify the inhibitory effects of isorhamnetin in EGFR-mediated skin cancer, we used two types of experimental models, including an EGF-induced JB6 cell transformation assay, and a mouse xenograft model of A431 cells. JB6 mouse epidermal cells are a welldeveloped cell culture system for studying tumor promotion ex vivo. This model comprises two phenotypes, promotion-sensitive (P+) and promotion-resistant (P-) JB6 mouse epidermal cell lines (30, 31) . JB6 P+ cells, but not P-cells, are irreversibly transformed by a tumor promoter, such as EGF. This process represents the pre-neoplastic-to-neoplastic progression.
In contrast, the A431 cell line was derived from an 85-year-old female with skin epidermal carcinoma. Because this cell line highly overexpresses EGFR, forms colonies when cultivated in soft agar and develops tumors in nude mice, it is an excellent model for studying Isorhamnetin is a dietary flavonoid, found in apples, blackberries, and pears (35) . It is also a major plasma metabolite of quercetin, which is a highly abundant flavonoid found in many dietary plants (36) . Recent studies showed that isorhamnetin exerts chemopreventive effects against cancer, cardiovascular disease, obesity, and Alzheimer's disease (15, 17, 18) .
These studies have attributed the major chemopreventive mechanism of isorhamnetin to its antioxidant effects. Indeed, many reports have suggested that the health benefits of other flavonoids as well as isorhamnetin come from antioxidant effects, because they are strong antioxidants (37) . Nonetheless, the proposed antioxidant effects cannot explain all of the effects of most flavonoids, such as the low effective dose and specific inhibition of oncogenic signal transduction pathways. Our findings and other previous studies suggest that flavonoids can also act as specific kinase inhibitors (38) .
A strong link has been reported between inflammation and carcinogenesis (39).
COX-2, a major mediator of inflammation, and its product, prostaglandin E 2 (PGE 2 ), enhance carcinogenesis (22) , increasing both the number of cells during the exponential growth phase and the number of colonies formed in soft agar (40) . Knockout of cox-2 results in reduced tumor formation and progression, and epidemiological studies and animal experiments demonstrated that nonsteroidal anti-inflammatory drugs targeting COX-2 can reduce the incidence of colorectal carcinoma (41) . Thus, COX-2 has been recognized as a molecular target of many chemopreventive as well as anti-inflammatory agents. In the present study, isorhamnetin inhibited EGF-induced COX-2 protein expression in JB6 cells and in A431 cells.
These results indicate that COX-2 is the target of isorhamnetin and that isorhamnetin has chemopreventive potential.
MEK1 is a dual-specificity protein kinase that phosphorylates ERK1/2 at specific 
